Close Menu

collaboration

Onconova will use Mission Bio's Tapestri platform to study rigosertib — a drug that Onconova is developing — to target the RAS mutation in myelodysplastic syndromes.

The company has signed a new, multiyear agreement with the Korean health system to build a data sharing network to support precision cancer care in East Asia.

The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.

The software firm will use NGS data from patient biopsies to create molecular profiles and offer individualized cancer treatment recommendations.

The partners will glean real-world evidence from Syapse's network of health system partners with the aim of informing precision oncology approaches and advancing research.

The partners are working together to advance tests that will identify which cancer patients have Notch activating mutations and fusions.

AmoyDx and Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development.

Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.

The mCODE team recently released standards for inputting genomic and other data into patient records to boost patient record transferability and trial participation.

Caris will use its whole-transcriptome sequencing assay and Molecular Intelligence Trials service to identify patients for a phase II clinical trial.

Pages